Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
May 21, 2019OncoCyte Presents Positive Results from R&D Validation Study of DetermaVu™ at the American Thoracic Society 2019 International Conference
Results were achieved using blood gene expression biomarkers alone and without the use of clinical parameters Company remains on-track to make DetermaVu™ commercially available in 2H 2019 ALAMEDA, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today presented results from the Company’s R&D Validation study at the American Thoracic Society (ATS) 2019 International Conference, whi... 
Printer Friendly Version
May 14, 2019OncoCyte Provides Corporate Update and Reports First Quarter 2019 Financial Results
Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the first quarter ended March 31, 2019 and provided a corporate update.  “During t... 
Printer Friendly Version
May 08, 2019OncoCyte to Report First Quarter 2019 Financial Results on Tuesday, May 14
Company to host conference call and webcast at 4:30pm ET ALAMEDA, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter ended March 31, 2019, on Tuesday, May 14, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 14, 2019 at 4:30 pm ET / ... 
Printer Friendly Version
April 01, 2019OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the fourth quarter and year ended December 31, 2018 and provided a corporate update.  “OncoCyte has made outstanding progress since our last quarterly update to investor... 
Printer Friendly Version
April 01, 2019OncoCyte to Present Late Breaking Abstract at the American Thoracic Society 2019 International Conference
Poster presentation and discussion to detail compelling results from R&D Validation study of the Company’s DetermaVu™ liquid biopsy test for the early detection of lung cancer ALAMEDA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that a late breaking abstract has been accepted for a poster presentation and discussion session at the American Thoracic Society 2019... 
Printer Friendly Version
March 25, 2019OncoCyte to Report Fourth Quarter and Full-Year 2018 Financial Results on Monday, April 1, 2019
ALAMEDA, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31, 2018, on Monday, April 1, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Monday, April 1, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along wi... 
Printer Friendly Version
March 06, 2019OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston
ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting at the Cowen and Company 39th Annual Health Care Conference, taking place March 11-13 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.  Cowen and Company 39th Annual Health Care Conference Date:  ... 
Printer Friendly Version
March 04, 2019OncoCyte Announces Initiation of Analytical Validation Study
Company remains on-track for commercial availability of DetermaVu™ Lung in 2H 2019 ALAMEDA, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the Company’s Analytical Validation study of DetermaVu™ Lung, its liquid biopsy test for lung cancer. Having recently achieved very positive results from its R&D Validation study, OncoCyte is now working to... 
Printer Friendly Version
February 12, 2019OncoCyte Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering. Following the exercise in full by the underwriters of their option to purchase up to an additional 1,400,000 shares of common stock at the public offering price, OncoCyte sold 10,733,334 shares of its common stock at a public offering pr... 
Printer Friendly Version
February 08, 2019OncoCyte Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $3.75 per share, for aggregate gross proceeds of approximately $35 million. OncoCyte has granted the underwriters a 30-day option to purchase up to an additional 1,400,... 
Printer Friendly Version
February 07, 2019OncoCyte Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by OncoCyte. OncoCyte intends to use the net proceeds of the public offering to support its DetermaVu™ comme... 
Printer Friendly Version
January 29, 2019OncoCyte Announces Successful Results of DetermaVu™ R&D Validation Study
Results show 90% sensitivity and 75% specificity, demonstrating best-in-class performance On track for commercial availability of  DetermaVu™ Lung in 2H 2019 Results suggest the potential to address a U.S. market opportunity of $4.7 billion Unique immune system interrogation approach may have potential for early detection of other cancers Company to host conference call today at 8:30am ET ALAMEDA, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a de... 
Printer Friendly Version
January 28, 2019OncoCyte Schedules Announcement and Conference Call to Discuss Results from Key R&D Validation Study of DetermaVu™
Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET ALAMEDA, Calif, Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today scheduled an announcement and conference call to discuss results of the Company’s key R&D Validation Study of DetermaVu™, its confirmatory liquid biopsy test that OncoCyte is developing to facilitate clinical decision making in lung cancer diagnosis. Ma... 
Printer Friendly Version
January 24, 2019Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided top-line 12 month data from the Company’s Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury (SCI). All 25... 
Printer Friendly Version
January 09, 2019AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity and Type II diabetes a... 
Printer Friendly Version
January 03, 2019OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
Ion GeneStudio™ S5 Demonstrates Generation of Consistent and Reproducible Results in Lung Cancer Studies ALAMEDA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced its successful transition to the Ion GeneStudio S5 next-generation sequencing (NGS) platform for targeted sequencing. The platform was chosen by OncoCyte after evaluating four leading platforms. OncoCyte... 
Printer Friendly Version
January 02, 2019AgeX Therapeutics to Present at Biotech Showcase 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California. AgeX Founder and CEO Michael D. West, Ph.D., will be speaking at the conference as follows: Date: Wednesday, ... 
Printer Friendly Version